nach oben

Diabetologia

Erschienen in:

01.01.2006 | Editorial

Troglitazone: the lesson that nobody learned?

verfasst von: Edwin A. M. Gale

Erschienen in: Diabetologia | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Excerpt

H. G. Wells once wrote a story about a man who travelled in time to a future world. There he encountered members of a beautiful race called the Eloi, who lived carefree lives of sylvan innocence on the surface of the planet, and tried hard to ignore the existence of the Morlocks, an ugly race that lived out of sight under the ground and preyed upon the Eloi for food and slaves. It would of course be too extreme to suggest that this might be taken as a parable of the relationship between the medical profession and the pharmaceutical industry, but there can be no doubt that there are things the medical Eloi prefer not to know, and that the pharmaceutical Morlocks choose not to talk about. The troglitazone story is among them. …

Anonymous (1999) The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623–634CrossRef

Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 346:393–403.CrossRef

Willman D (2000) The rise and fall of the killer drug Rezulin. Los Angeles Times, 4 June. Reprint available from http://www.lef.org/magazine/mag2000/sep2000_report_rezulin.html, last accessed in October 2005

National Institute of Diabetes and Digestive and Kidney Diseases (1998) NIDDK discontinues troglitazone arm of "Diabetes Prevention Program" clinical trial. NIDDK, Bethesda. Available from http://www.niddk.nih.gov/welcome/releases/6_4_98.htm, last accessed in October 2005

Willman D (1998) Drug maker hires NIH researcher. Los Angeles Times, 7 December. Available from http://www.house.gov/waxman/news_files/news_letters_rezulin_press_NIH_sci_denies_12_7_98.htm, last accessed in October 2005

Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl J Med 331:1188–1193PubMedCrossRef

Olefsky J, Antonucci T, Lockwood D, Norris R. Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus. US Patent 5,478,852, filed 23 August 1994. Available from http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm&r=1&f=G&l=50&s1=5,478,852.WKU.&OS=PN/5,478,852&RS=PN/5,478,852, last accessed in October 2005

Olefsky J. Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus. US Patent 5,708,012, filed 28 April 1995. Available from http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm&r=1&f=G&l=50&s1=5708012.WKU.&OS=PN/5708012&RS=PN/5708012, last accessed in October 2005

Varmus H (1998) Letter to Henry A. Waxman, House of Representatives, 29 December. Available from http://www.henrywaxman.house.gov/news_files/news_letters_rezluin_2_19_99_NIH_response.htm, last accessed in October 2005

10.

US Department of Health and Human Services/Food and Drug Administration (1997) FDA approves rezulin for diabetes patients poorly controlled on insulin therapy. FDA Talk Paper, 30 January. Available from http://www.fda.gov/bbs/topics/ANSWERS/ANS00783.html, last accessed in October 2005

11.

Anonymous (1995) Warner-Lambert Company. Corporate Crime Reporter 46, 4 December. Available from http://www.corporatecrimereporter.com/top100.html#Annotated, last accessed in October 2005

12.

US Department of Health and Human Services/Food and Drug Administration (1996) Endocrinologic and Metabolic Drugs Advisory Committee. Troglitazone for diabetes mellitus. Meeting no. 65. USDHHS/FDA, Bethesda, 11 December. Available from http://www.fda.gov/ohrms/dockets/ac/96/transcpt/3255t2a.pdf; http://www.fda.gov/ohrms/dockets/ac/96/transcpt/3255t2b.pdf; http://www.fda.gov/ohrms/dockets/ac/96/transcpt/3255t2c.pdf;http://www.fda.gov/ohrms/dockets/ac/96/transcpt/3255t2d.pdf; all last accessed in October 2005

13.

King KF (2000) Letter to Jane E. Henney, Food and Drug Administration. Parke-Davis, Morris Plains, 20 March. Available from http://web.archive.org/web/20001015184650/www.warner-lambert.com/Rezulin/henney.html, last accessed in October 2005

14.

IMS Health (1998) Business Watch: 1997 at a glance. IMS Health, Fairfield

15.

Anonymous (1997) Troglitazone (Romozin) withdrawn. Current Problems in Pharmacovigilance 23:13–16. Available from http://www.mhra.gov.uk/home/groups/pl-p/documents/publication/con007478.htm#Troglitazone, last accessed in October 2005

16.

Wolfe SM (2000) Letter to the FDA requesting a criminal investigation of Warner Lambert/Parke Davis for what appears to be illegally delaying the submission of data known to the company before troglitazone was marketed. HRG Publication #1515. Public Citizen’s Health Research Group, Washington, 14 March. Available from http://www.citizen.org/publications/print_release.cfm?ID=6716, last accessed in October 2005

17.

Graham D, Green L (2000) Memorandum. Final report: Liver failure risk with troglitazone (Rezulin) NDA: 20–720. USDHHS, FDA, Center for Drug Evaluation and Research, Bethesda. 19 December

18.

Sigmund WR 2nd (1997) Dear Healthcare Professional. Parke-Davis, Morris Plains, 1 December. Available from http://www.fda.gov/medwatch/SAFETY/1997/rezul3.htm, last accessed in October 2005

19.

Watkins PB, Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. New Engl J Med 338:916–917PubMedCrossRef

20.

Wolfe SM, Sasich L (1998) Petition to the Food and Drug Administration to ban troglitazone/Rezulin due to its causing several cases of liver failure. HRG Publication #1449. Public Citizen’s Health Research Group, Washington, 27 July. Available from http://www.citizen.org/publications/release.cfm?ID=6647, last accessed in October 2005

21.

Wolfe SM (1999) Statement before the Food and Drug Administration Endocrine and Metabolic Drugs Advisory Committee meeting advising them to withdraw troglitazone from the U.S. Market. HRG Publication #1476. Public Citizen’s Health Research Group, Washington, 26 March. Available from http://www.citizen.org/publications/release.cfm?ID=6674, last accessed in October 2005

22.

Horwitz KB, Mallin SR (1999) Letter to Endocrinologic & Metabolic Drug Advisory Committee on Rezulin. Re: Rezulin (troglitazone). Endocrine Society, Bethesda, 24 March. Available from http://www.endo-society.org/publicpolicy/legislative/letters/fdaletter.cfm, last accessed in October 2005

23.

Gale EAM (2001) Lessons from the glitazones: a story of drug development. Lancet 357:1870–1875

24.

DeRenzo EG (2005) Conflict-of-interest policy at the National Institutes of Health: the pendulum swings wildly. Kennedy Inst Ethics J 15:199–210PubMedCrossRef

25.

Gale EAM (2003) Between two cultures: the expert clinician and the pharmaceutical industry. Clin Med 3:538–541PubMed

Titel: Troglitazone: the lesson that nobody learned?
verfasst von: Edwin A. M. Gale
Publikationsdatum: 01.01.2006
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 1/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-005-0074-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Increased expression of cyclooxygenase-2 in human pancreatic islets treated with high glucose or ligands of the advanced glycation endproduct-specific receptor (AGER), and in islets from diabetic mice

The impact of ethnicity on glucose regulation and the metabolic syndrome following gestational diabetes

Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects

Diabetes mellitus and impaired fasting glucose in Alaska Eskimos: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study

Activator protein-1 in epiretinal membranes of patients with proliferative diabetic retinopathy

Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women’s Heart and Health Study